Literature DB >> 27910003

Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia.

Manar M Ismail1,2, Nahla A B Abdulateef3,4.   

Abstract

Acute myeloid leukemia (AML) is an aggressive malignancy for which overall disease-free survival is less than 50%. Manipulation of the immune system is an interesting and promising therapy for AML patients. We aimed to characterize the immune system of AML patients, highlighting the clinical relevance of total bone marrow (BM) lymphocytes and subpopulations. Sixty-six new AML cases diagnosed according to WHO criteria from King Abdullah Medical City, KSA, from October 2012 to February 2015. Analysis of BM lymphocytes and subpopulations was done by flowcytometry. Significantly, high percentages of BM lymphocytes, T cells, and natural killer (NK) cells were detected in the group that achieved complete remission (P values = 0.004, <0.001, and <0.001, respectively). Overall survival (OS) was significantly prolonged in patients with high BM lymphocytes and T cells (P values = 0.047 and P 0.002, respectively). Multivariate analysis indicated that BM T-cell percentage and cytogenetics were independent prognostic factors predictive of OS (HR 4.7, P value = 0.011). BM T-cell percentage constitutes a novel host factor that can be used in combination with cytogenetics to better predict OS. Large-scale multicenter studies are recommended to clarify its role as a predictor of OS and leukemia-free survival.

Entities:  

Keywords:  AML; BM lymphocytes; Natural killer cells; OS; Prognosis; T-cells

Mesh:

Year:  2016        PMID: 27910003     DOI: 10.1007/s12185-016-2153-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  31 in total

Review 1.  Natural killer cell immune escape in acute myeloid leukemia.

Authors:  E Lion; Y Willemen; Z N Berneman; V F I Van Tendeloo; E L J Smits
Journal:  Leukemia       Date:  2012-03-26       Impact factor: 11.528

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 3.  Immunotherapy for Acute Myeloid Leukemia.

Authors:  Felix S Lichtenegger; Christina Krupka; Thomas Köhnke; Marion Subklewe
Journal:  Semin Hematol       Date:  2015-03-17       Impact factor: 3.851

4.  Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution.

Authors:  M B Vidriales; A Orfao; M C López-Berges; M González; J M Hernandez; J Ciudad; A López; M J Moro; M Martínez; J F San Miguel
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

Review 5.  The anticancer immune response: indispensable for therapeutic success?

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Fabrice André; Antoine Tesniere; Guido Kroemer
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

Review 6.  The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer.

Authors:  Roy M Bremnes; Lill-Tove Busund; Thomas L Kilvær; Sigve Andersen; Elin Richardsen; Erna Elise Paulsen; Sigurd Hald; Mehrdad Rakaee Khanehkenari; Wendy A Cooper; Steven C Kao; Tom Dønnem
Journal:  J Thorac Oncol       Date:  2016-02-01       Impact factor: 15.609

7.  Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies.

Authors:  Guillermo De Angulo; Carrie Yuen; Shana L Palla; Peter M Anderson; Patrick A Zweidler-McKay
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

8.  Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses.

Authors:  Colleen M Lau; Simone A Nish; Nir Yogev; Ari Waisman; Steven L Reiner; Boris Reizis
Journal:  J Exp Med       Date:  2016-02-22       Impact factor: 14.307

Review 9.  Targeting the innate immune system as immunotherapy for acute myeloid leukemia.

Authors:  Emily Curran; Leticia Corrales; Justin Kline
Journal:  Front Oncol       Date:  2015-04-09       Impact factor: 6.244

Review 10.  Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis.

Authors:  X Yu; Z Zhang; Z Wang; P Wu; F Qiu; J Huang
Journal:  Clin Transl Oncol       Date:  2015-10-12       Impact factor: 3.405

View more
  10 in total

Review 1.  Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.

Authors:  Jan Philipp Bewersdorf; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Anticancer Ther       Date:  2019-03-19       Impact factor: 4.512

2.  Serial Evaluation of T cell Subsets in Paediatric Acute Myeloid Leukaemia- a Prospective Study.

Authors:  Anuj Kumar Bansal; Surender Kumar Sharawat; Ritu Gupta; Sreenivas Vishnubhatla; Sameer Bakhshi
Journal:  Indian J Hematol Blood Transfus       Date:  2021-04-16       Impact factor: 0.900

Review 3.  Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Authors:  Georgios Petros Barakos; Eleftheria Hatzimichael
Journal:  Diseases       Date:  2022-06-10

Review 4.  Immune escape and immunotherapy of acute myeloid leukemia.

Authors:  Luca Vago; Ivana Gojo
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 5.  Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.

Authors:  Adam J Lamble; Evan F Lind
Journal:  Front Oncol       Date:  2018-06-13       Impact factor: 6.244

6.  Comparison of multi-omics results between patients with acute myeloid leukemia with long-term survival and healthy controls.

Authors:  Yang Song; Qishan Hao; Guangji Zhang; Qiuyun Fang; Zhe Wang; Yan Li; Hui Wei; Ying Wang; Erlie Jiang; Zheng Tian; Yannan Jia; Min Wang; Jianxiang Wang; Yingchang Mi
Journal:  Ann Transl Med       Date:  2022-01

Review 7.  Single-Cell Technologies to Decipher the Immune Microenvironment in Myeloid Neoplasms: Perspectives and Opportunities.

Authors:  Chiara Caprioli; Iman Nazari; Sara Milovanovic; Pier Giuseppe Pelicci
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 5.738

8.  Study of Bone Marrow Lymphocyte Subset in Acute Myeloid Leukemia.

Authors:  Prasad Dange; Seema Tyagi; Richa Juneja; Tulika Seth; Renu Saxena
Journal:  J Lab Physicians       Date:  2021-07-29

9.  Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.

Authors:  Adam J Lamble; Yoko Kosaka; Ted Laderas; Allie Maffit; Andy Kaempf; Lauren K Brady; Weiwei Wang; Nicola Long; Jennifer N Saultz; Motomi Mori; David Soong; Clare V LeFave; Fei Huang; Homer Adams; Marc M Loriaux; Cristina E Tognon; Pierrette Lo; Jeffrey W Tyner; Guang Fan; Shannon K McWeeney; Brian J Druker; Evan F Lind
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-08       Impact factor: 11.205

Review 10.  Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia.

Authors:  Anna Aureli; Beatrice Marziani; Tommaso Sconocchia; Maria Ilaria Del Principe; Elisa Buzzatti; Gianmario Pasqualone; Adriano Venditti; Giuseppe Sconocchia
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.